Basel Breast Consortium
Regulatory approval of the Phase I-IIA study for CB-103 by Swissmedic
On October 3rd Cellestia received approval of its first-in-human Phase I – IIa clinical study with CB-103 in Switzerland.
The NOTCH Meeting
Cellestia Biotech has presented a poster at the NOTCH meeting on October 1st–5th in Athens.